14 Recruiting Studies Using Lutetium Lu 177 Dotatate
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Lutetium Lu 177 Dotatate
Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Metastatic Digestive System Neuroendocrine Neoplasm
View Study & Checklist ➔Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
📍 Fairbanks Memorial Hospital — Fairbanks, Alaska
Metastatic Pancreatic Neuroendocrine Tumor
View Study & Checklist ➔Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Neuroendocrine Neoplasm
View Study & Checklist ➔Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Metastatic Neuroendocrine Tumor
View Study & Checklist ➔177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry
📍 Holden Comprehensive Cancer Center at the University of Iowa — Iowa City, Iowa
Neuroendocrine Tumors
View Study & Checklist ➔Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
📍 Emory University Hospital Midtown — Atlanta, Georgia
Digestive System Neuroendocrine Tumor
View Study & Checklist ➔Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Advanced Lung Neuroendocrine Tumor
View Study & Checklist ➔Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Metastatic Digestive System Neuroendocrine Tumor G1
View Study & Checklist ➔Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
📍 Mayo Clinic in Rochester — Rochester, Minnesota
Grade 1 Meningioma
View Study & Checklist ➔Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
📍 Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Digestive System Neuroendocrine Tumor G1
View Study & Checklist ➔177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
📍 OHSU Knight Cancer Institute — Portland, Oregon
Anatomic Stage IV Breast Cancer AJCC v8
View Study & Checklist ➔Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Metastatic Pancreatic Neuroendocrine Tumor
View Study & Checklist ➔Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
📍 University of Iowa Hospitals and Clinics — Iowa City, Iowa
Merkel Cell Carcinoma
View Study & Checklist ➔Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation
View Study & Checklist ➔